'Docetaxel' diaporamas de présentation

1.26k views • 109 slides

ASCO Update 2004: Focus on Prostate and Renal Cell Cancers Primo N. Lara, Jr., MD

ASCO Update 2004: Focus on Prostate and Renal Cell Cancers Primo N. Lara, Jr., MD Associate Professor University of California Davis Cancer Center. Development of Hormonal Escape. Androgen-independent cells take over. Deprive androgen. Responsive. Cell numbers. Dependent. Independent.

848 views • 70 slides

Taxotere in the Management of Early-Stage Breast Cancer: Improving Outcomes

764 views • 47 slides

Taxotere in the Management of Early-Stage Breast Cancer: Improving Outcomes

595 views • 47 slides

Ongoing Trials and the Future In Hormone Refractory Prostate Cancer

Ongoing Trials and the Future In Hormone Refractory Prostate Cancer. Cora N. Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy. Novel Therapies and Targets for Prostate Cancer Can We Improve Upon the Results with Docetaxel ?.

425 views • 42 slides

Il trattamento del carcinoma della prostata in fase di resistenza alla castrazione

Il trattamento del carcinoma della prostata in fase di resistenza alla castrazione. Giuseppe Procopio, MD, . 2002 2004 . . . . . . . . . . . . . . . . . 2010 2011. Treatment options for patients with CRPC. Zoledronic Acid 1. Sipuleucel-T 3.

682 views • 37 slides

Treatment Options for Docetaxel refractory patients

Treatment Options for Docetaxel refractory patients. Winston W Tan MD FACP Senior Consultant Hematology/Oncology Genitourinary Oncology Mayo Clinic College of Medicine. Learning Objectives.

623 views • 33 slides

Study sponsored by Aventis Oncology, RP56976-V-316 / TAX 316

BCIRG 001 Study. Phase III Trial Comparing TAC with FAC in the Adjuvant Treatment of Node Positive Breast Cancer Patients: Interim Analysis.

436 views • 28 slides

The future of our patients already treated with first line chemotherapy

235 views • 23 slides

Difficulties with network meta-analysis when starting to use PD-L1 thresholds

Difficulties with network meta-analysis when starting to use PD-L1 thresholds. Disclaimer. The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to AstraZeneca. Summary presentation.

235 views • 22 slides

A Road-Map to Integrated Biomarker Studies

A Road-Map to Integrated Biomarker Studies. George R. Simon, MD Hollings Cancer Center Medical University of South Carolina Charleston, SC. Stepwise Approach. Clinical trials Portfolio - Obtain funding for and open a series of investigator initiated studies

462 views • 21 slides

Figure1

225 views • 9 slides

Figure1

92 views • 9 slides

Authors: Scher HI et al, ASCO 2010 Abstract: 4509 Reviewed by: Dr. Lori Wood

Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT 2 trial. Authors: Scher HI et al, ASCO 2010 Abstract: 4509 Reviewed by: Dr. Lori Wood

197 views • 7 slides

New Drug for Prostate Cancer Gets FDA Nod

New Drug for Prostate Cancer Gets FDA Nod. http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html?ref=policy&_r=0. Andrew Pollack The New York Times August 31, 2012. Prostate Cancer. Expected 241,000 new cases this year and 28,000 deaths

246 views • 6 slides

New Drug for Prostate Cancer Gets FDA Nod

New Drug for Prostate Cancer Gets FDA Nod. http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html?ref=policy&_r=0. Andrew Pollack The New York Times August 31, 2012. Prostate Cancer. Expected 241,000 new cases this year and 28,000 deaths

62 views • 6 slides

Gastric Cancer Treatment with Docetaxel

https://www.cancercurepharmacy.com/BlogDetails.aspx?Title=Gastric-Cancer-Treatment-with-Docetaxel Docetaxel brand name Taxotere is an anti-cancer chemotherapy medication which is classified as an anti-microtubule agent. This medication has been in the market since 2004 and has shown tremendous results among patients. Chemotherapy drugs kill the cancer cells depends upon their ability on how fast they halt the division of cells. Docetaxel medicationu2019s main function is to damage the DNA or RNA cells which copy itself in the division. With this drug working, cancer cells are not able to divide, thus leading to the death of these cells. Antimicrotubule agents like Docetaxel (Brand Taxotere) inhibits the microtubule structures within cells. These microtubules play a major role in replicating and dividing of cells, and docetaxel results in the untimely death of these cells.

73 views • 4 slides

How Docetaxel is used for the Treatment of Different Cancers

https://www.cancercurepharmacy.com/BlogDetails.aspx?Title=How-Docetaxel-is-used-for-the-Treatment-of-Different-Cancers Docetaxel (Brand Taxotere) is a chemotherapeutic medication that is prescribed for the treatment of several kinds of cancers including head & neck cancer, prostate cancer, etc. Docetaxel / Taxotere is often used with other cancer medications for different kinds of cancers. Docetaxel is received as an injection into the vein by a healthcare provider in a clinic or hospital setting. It can cause harm to the skin if it comes into direct contact. After receiving the Docetaxel injection, it is important to inform your caregiver if you experience any pain, burning or swelling around or on the injected area.

47 views • 4 slides

Table 3 Karnofsky performance status

492 views • 1 slides

Results

Inhibition of SHH signaling enhances Docetaxel efficacy in castration-resistant prostate cancer cells Sierra L. Lawhorne 1,2 , Sakthivel Muniyan 1 , Parthasarathy Seshacharyulu 1 , Ming-Fong Lin 1,3 , and Surinder K. Batra 1,3

53 views • 1 slides